An observational study in Breast Cancer, sponsored by Kenko Imalytics S.L.. Recruiting at 1 site in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.
Sponsored by Kenko Imalytics S.L. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 905 studies in Breast Neoplasms with a site in Spain — 164 open to participants now, 285 under way, 84 of them phase 3. Breast Neoplasms · Spain.
Among the 905 studies in Breast Neoplasms with a site in Spain, this one is the 49th largest by planned enrollment of the 97 observational ones that give a count, is one of 27 that started in 2026, is one of 97 observational ones, reaches primary completion later than 153 of the 284 other live ones, and was the 892nd registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →164 of the 905 studies in Breast Neoplasms with a site in Spain are open now. Recruiting first, the newest first:
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia · Sites in Spain
Ages 18+
Spanish Breast Cancer Research Group · Sites in Spain
Ages 18+
Daiichi Sankyo · Sites in Spain, United States, Belgium and 5 more countries
Ages 18+
Spanish Breast Cancer Research Group · Sites in Spain
Ages 18+ · Women only
UNICANCER · Sites in Spain, Belgium, France and 4 more countries
Ages 35–45 · Women only
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
905 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 174 · Phase 2 327 · Phase 3 224 · Phase 4 13
First in 1996; this study’s year is marked. 27 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is close to the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 151 across the 805 interventional studies, 200 across the 97 observational. Of the 576 that completed or were terminated, 291 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
533 of 905 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Kenko Imalytics S.L. as lead sponsor.
Kenko Imalytics S.L. has 1 study filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
78 of the studies in Breast Neoplasms with a site in Spain that are under way reach primary completion within a year, 20 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03820830Phase 3ETOP IBCSG Partners FoundationPalbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer | 2026-12 |
| NCT03595592Phase 3Fondazione MichelangeloNeoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer | 2026-12-15 |
| NCT05909397Phase 3PfizerVepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | 2026-12-30 |
| NCT05038735Phase 3Novartis PharmaceuticalsStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. | 2027-01-28 |
| NCT04208178Phase 3Novartis PharmaceuticalsStudy of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | 2027-02-26 |
Add all 78 to your calendar (.ics) → With an account.
Among the 905 studies in Breast Neoplasms with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn whether a new medical software tool called Kenko Breast AI+ can help healthcare professionals read breast magnetic resonance imaging (MRI) scans better to help diagnose breast cancer. The study includes adult women who may have breast cancer or who are being followed for the disease.
The main questions it aims to answer is:
Researchers will compare MRI readings done with the software to readings done without it.
Participants will attend their regularly scheduled breast MRI appointment. All diagnoses are based on standard medical care, not on the study software.
This clinical investigation is a study designed to assess the safety, diagnostic performance, and usability of Kenko Breast AI+, a medical device software intended to support breast cancer diagnosis using breast MRI.
The study is includes adult women who undergo breast MRI as part of routine clinical care for suspected breast cancer or oncological surveillance. The study does not alter standard clinical management and does not introduce additional diagnostic or therapeutic procedures.
Independent radiologist readers assess MRI examinations either with or without assistance from Kenko Breast AI+. Each MRI case is evaluated once per reader during the first assessment phase and reassessed after a washout period using the alternate method. The sequence of assessments and reader allocation is randomized. Reader assessments are compared with a reference diagnosis established according to routine clinical practice.
MRI datasets acquired during routine care are reviewed for technical quality, pseudonymized at the study site, and uploaded to both the investigational software platform and the site's picture archiving and communication system (PACS). Readers access the assigned cases through the appropriate platform according to randomization. After study completion, readers complete usability evaluations of the investigational device.
The study is conducted in accordance with ISO 14155:2020, Good Clinical Practice, and applicable regulatory requirements (EU Medical Device Regulation 2017/745). Quality assurance measures include site qualification and initiation, staff training, predefined workflows, and documented delegation of responsibilities.
Monitoring activities are performed by an independent sponsor-appointed monitor and include on-site and remote visits, verification of protocol compliance, review of safety reporting, and assessment of data accuracy. Study close-out procedures confirm completeness and proper archiving of study documentation. Audits and regulatory inspections may be conducted as required.
Study data are recorded in validated electronic data capture systems using predefined case report forms. Automated and manual data checks are applied to ensure completeness, consistency, and plausibility. Discrepancies or missing values are resolved through a formal query process, and all data modifications are documented in audit trails. Source data verification is performed during monitoring visits by comparing electronic case report form entries with original source documents.
A total of 200 participants are included to provide adequate precision for estimating diagnostic performance parameters. The sample size is based on assumptions of sensitivity and specificity greater than 85% and a predefined acceptable margin of error. The planned enrollment exceeds that of many published diagnostic imaging studies and is considered sufficient for the study objectives.
MRI cases or lesions without an established reference diagnosis are excluded from primary diagnostic performance analyses. Reasons for missing data are documented and summarized. Descriptive comparisons are performed to assess potential bias. Invalid or technically inadequate MRI datasets are excluded according to predefined criteria.
Analyses are conducted according to a predefined statistical analysis plan. Analysis populations include full analysis, per-protocol, and safety sets. Diagnostic performance measures are calculated and compared between assessments with and without the investigational device. Interpretation time and inter-reader agreement are evaluated using appropriate statistical methods. Usability outcomes are summarized descriptively.
Data processing complies with applicable data protection regulations, including the EU General Data Protection Regulation 2016/679. The study is conducted in accordance with the Declaration of Helsinki and applicable regulatory and ethical requirements. Ethics committee approval is obtained prior to study initiation. As the study is observational and does not impact clinical decision-making, it is considered to pose minimal risk to participants.
Prospective data will be collected from adult women with suspected or diagnosed breast cancer undergoing breast MRI as part of routine clinical care at Hospital Universitario del Vinalopó.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Women with suspected breast cancer or under surveillance for the disease who have undergone MRI including perfusion (DCE-MRI), diffusion (DTI-MRI) and T2 sequences, performed for the purposes of:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult women with suspected breast cancer or under surveillance for the disease
Device: Kenko Breast AI+
Kenko Breast AI+ is a medical software that processes breast magnetic resonance imaging (MRI) sequences to generate parametric maps of imaging biomarkers related to vascularization and cellularity. These maps assist radiologists in detecting, characterizing, and grading breast lesions, supporting diagnosis of malignancy and assessment of tumor aggressiveness. The software functions as a non-invasive imaging biomarker tool intended to complement, not replace, molecular and histopathological diagnostics. Kenko Breast AI+ is a Class IIb medical device. The assessment of MRI breast cases with Kenko Breast AI+ will be compared with the assessment of MRI breast cases without Kenko Breast AI+ as per routine clinical practice. The ground truth diagnosis will be established by routine clinical practice and may include a combination of clinical assessment, imaging results, tissue biopsy, and pathology reports.
The False Positive (FP), False Negatives (FN), True Positives (TP), and True Negatives (TN) rates.
The False Positive (FP), False Negatives (FN), True Positives (TP), and True Negatives (TN) rates expressed in integer numbers and in percentage for total results for assessment with and without the study device.
Time frame: Through MRI cases assessment during the study period (Months 1 to 11)
Interpretation time.
The interpretation time, measured in minutes, for assessment with and without the study device.
Time frame: Through MRI cases assessment during the study period (Months 1 to 11)
The occurrence of non-serious and serious device-related, or device procedures-related adverse events, and device deficiencies.
Safety events frequency.
Time frame: From enrollment through study completion (assessed up to 11 months)
Sensitivity, specificity, positive predictive value, negative predictive value, positive and negative likelihood ratios, and odds ratio for assessment with and without the study device.
Time frame: Through MRI cases assessment during the study period (Months 1 to 11)
Descriptive breast lesion characteristics, including lesion breast, lesion location, lesion third, lesion type, lesion extension, Breast Imaging Reporting and Data System (BI-RADS) classification, and level of aggressiveness.
Time frame: Through MRI cases assessment during the study period (Months 1 to 11)
Level of confidence in MRI assessment with and without the study device.
Five-point Likert confidence scale, ranging from 1 - Not confident at all to 5 -Extremely confident. Higher values indicate higher confidence in the MRI assessment with and without the study device.
Time frame: Through MRI cases assessment during the study period (Months 1 to 11)
Inter-reader concordance
Inter-reader concordance for assessment with the study device
Time frame: Before study initiation (5 training cases)
Usability of the study device assessed by System Usability Scale (SUS)
Usability of the study device assessed for each reader using the SUS, a standardized 10-item questionnaire with items that alternate between positively and negatively worded statements to reduce response bias. Each item is rated on a 5-point Likert scale, ranging from 1-Strongly disagree to 5-Strongly agree. Responses are converted to a standardized scoring format and summed, with the total score multiplied by 2.5 to yield a final SUS score ranging from 0 to 100. Scores above 85 indicate excellent usability, while scores between 68 and 84 indicate good usability. The questionnaire is completed once per reader, after the reader has completed all MRI image assessments with and without the study device.
Time frame: At study completion, after each reader has completed all MRI image assessments with and without the study device (Month 11)
Usability of the study device assessed by task completion rate
Task completion rate assessed for each reader as the percentage of cases successfully processed with the study device without assistance or errors
Time frame: At study completion, after each reader has completed all MRI image assessments with and without the study device (Month 11)
Usability of the study device assessed by error rate
Error rate assessed for each reader as the percentage of cases processed with the study device in which the user encountered errors
Time frame: At study completion, after each reader has completed all MRI image assessments with and without the study device (Month 11)
Usability of the study device assessed by assistance rate
Assistance rate assessed for each reader as the percentage of cases processed with the study device in which the user requested assistance
Time frame: At study completion, after each reader has completed all MRI image assessments with and without the study device (Month 11)
Usability of the study device assessed by time-on-task
Time-on-task assessed for each reader as the average time the user spent completing a case assessment with the study device
Time frame: At study completion, after each reader has completed all MRI image assessments with and without the study device (Month 11)
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for May 2027, 10 months after the start.
Of 189 industry-sponsored observational studies under Breast Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 70. This study's planned 10 months is below that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.